Navigation Links
Boosting HIV screening can increase survival and is cost effective

Expanded HIV screening can increase patient life span, prevent the spread of the disease, and is cost effective, researchers at Yale, Harvard and the Massachusetts General Hospital report in the February 10 issue of the New England Journal of Medicine (NEJM).

The study's findings are part of a two-paper series in NEJM on the value of expanded HIV screening in the United States. The Yale/Harvard study used different data and methods than another study by VA, Duke and Stanford researchers, yet both teams reached roughly the same conclusions.

"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the U.S.," said Yale lead author A. David Paltiel, associate professor of health and policy administration in the Department of Epidemiology and Public Health at Yale School of Medicine. "Our findings, coupled with those of our colleagues, firmly establish the great value of expanded screening."

Paltiel and his team developed a mathematical model of HIV screening and treatment to predict the costs and benefits of HIV counseling, testing and referral. They found that routine, voluntary HIV screening every three to five years is cost-effective by U.S. standards, in all but the lowest-risk populations. Frequent HIV screening in moderate-to-high-risk populations could produce life expectancy gains at costs that compare favorably to many commonly employed screening interventions in other chronic conditions, including breast cancer, colorectal cancer, diabetes and hypertension. Paltiel said that even in settings with HIV infection levels similar to the U.S. general population, one-time screening could deliver excellent return on investment.

"HIV is a severe disease that, left untreated, produces substantial morbidity and mortality," said Paltiel. "It has a long asymptomatic phase, which can be diagnosed using very effective, inexpensive tests. Most importantly, early detection speeds link
'"/>

Source:Yale University


Page: 1 2

Related biology news :

1. Boosting The BCG Vaccine To Beat Tuberculosis
2. Boosting newborns immune responses
3. Boosting brain power -- with chocolate
4. MetaChip provides quick, efficient toxicity screening of potential drugs
5. Researchers develop assay that could be applied to drug screening
6. NIH creates nationwide network of molecular libraries screening centers
7. UT Southwestern researchers develop screening test for cells that activate immune system
8. Newborn screening can cause unnecessary parental stress
9. Handling HPV vaccines and screening: The views of 100 authors
10. Hair-growth drug artificially lowers PSA levels in prostate cancer screening, study finds
11. Sexual cooperation: Mating increases longevity in ant queens
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boosting HIV screening can increase survival and cost effective

(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
(Date:3/3/2015)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... odour control projects in North America , the ... . "Bidding activity in 2015 continues to be robust" ... high volume year for bidding in 2014, we are pleased to ... orders reflect the organization,s renewed focus on select market segments where ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)... , March 3, 2015  Thingee Corporation, a software ... delivering a presentation entitled, "Technology Adoption: Making Reps, Lives ... through Innovations and Technology ,  in Deerfield ... to 13, 2015. Audiences looking to learn how technology ... want to be in the audience for the Thingee ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Thingee to present at 11th Annual Synergistix Users Conference 2
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6
...
...
Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: